

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/696,002	10/30/2003	Jing-Shan Hu	PF112P3C2US	7776
22195	7590 04/14/2006		EXAMINER	
HUMAN GENOME SCIENCES INC INTELLECTUAL PROPERTY DEPT.			BORGEEST, CHRISTINA M	
	Y GROVE ROAD		ART UNIT	PAPER NUMBER
ROCKVILLE,	, MD 20850		1649	

DATE MAILED: 04/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/696,002	HU ET AL.	
Office Action Summary	Examiner	Art Unit	
	Christina Borgeest	1649	
The MAILING DATE of this communication app			-·
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 36(a). In no event, however, may a re will apply and will expire SIX (6) MONT cause the application to become ABA	ATION. ply be timely filed HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 14 Ja	anuary 2005.		
	action is non-final.		
3) Since this application is in condition for allowar	nce except for formal matte	rs, prosecution as to the merits is	
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D.	11, 453 O.G. 213.	
Disposition of Claims			
4)⊠ Claim(s) <u>30-80</u> is/are pending in the application	n.		
4a) Of the above claim(s) is/are withdraw			
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>30-80</u> are subject to restriction and/or	election requirement.		
Application Papers			
9) The specification is objected to by the Examine	er.		
10) The drawing(s) filed on is/are: a) acc		y the Examiner.	
Applicant may not request that any objection to the	drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correct	tion is required if the drawing(s) is objected to. See 37 CFR 1.121(d).	
11) ☐ The oath or declaration is objected to by the Ex	caminer. Note the attached	Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. §	119(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:1. ☐ Certified copies of the priority document	s have been received		
2. Certified copies of the priority document		polication No	
3. Copies of the certified copies of the prior			
application from the International Bureau	•	3	
* See the attached detailed Office action for a list	of the certified copies not i	eceived.	
Attachment(s)	_		
1) Notice of References Cited (PTO-892)		ummary (PTO-413) /Mail Date	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)		/Mail Date formal Patent Application (PTO-152)	
Paper No(s)/Mail Date	o) 🗀 Other	_ *	

Application/Control Number: 10/696,002

Art Unit: 1649

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 30-37, 61-64 are drawn to methods of contacting cells which have tyrosine kinase receptor that binds VEGF-2 with a polypeptide comprising a portion of SEQ ID NO: 2 or SEQ ID NO: 4, classified in class 514, subclass 2.
- II. Claims 38-60, 65-80 are drawn to a purified and isolated mammalian polypeptides having amino acid sequence set forth in SEQ ID NOs: 2 or 3, classified in class 530, subclass 300.

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case stimulating or modulating tyrosine kinase receptor activity and cell growth can be practiced with proteins other than those recited in Group I. Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Application/Control Number: 10/696,002

Art Unit: 1649

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

Page 3

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Application/Control Number: 10/696,002

Art Unit: 1649

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christina Borgeest whose telephone number is 571-272-4482. The examiner can normally be reached on 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christina Borgeest, Ph.D.

ELIZABETH KEMMERER PRIMARY EXAMINER

Elyaber C Kemmens